$111 Million is the total value of BML Capital Management, LLC's 31 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 45.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIL | SPDR SER TRbloomberg 1-3 mo | $18,364,000 | 0.0% | 200,000 | 0.0% | 16.52% | +4.1% | |
| SGOV | Buy | ISHARES TR0-3 mnth treasry | $18,113,400 | +44.1% | 180,000 | +44.0% | 16.29% | +49.9% |
| CYT | Buy | CYTEIR THERAPEUTICS INC | $8,450,000 | +47.6% | 3,250,000 | +3.3% | 7.60% | +53.6% |
| AVIR | New | ATEA PHARMACEUTICALS INC | $8,363,534 | – | 2,236,239 | +100.0% | 7.52% | – |
| ADVM | Sell | ADVERUM BIOTECHNOLOGIES INC | $8,199,915 | +61.7% | 5,157,179 | -27.0% | 7.38% | +68.3% |
| Sell | PARDES BIOSCIENCES INC | $6,862,856 | +30.4% | 3,791,633 | -4.9% | 6.17% | +35.7% | |
| TALS | Buy | TALARIS THERAPEUTICS INC | $6,080,000 | +67.6% | 2,000,000 | +3.7% | 5.47% | +74.4% |
| ATHA | ATHIRA PHARMA INC | $5,501,476 | +18.0% | 1,864,907 | 0.0% | 4.95% | +22.8% | |
| Sell | ELIEM THERAPEUTICS INC | $4,432,876 | -7.8% | 1,583,170 | -4.5% | 3.99% | -4.1% | |
| ANF | Sell | ABERCROMBIE & FITCH COcl a | $4,427,400 | -46.1% | 117,500 | -60.3% | 3.98% | -43.9% |
| ASTROTECH CORP | $3,121,006 | +32.8% | 220,410 | 0.0% | 2.81% | +38.2% | ||
| ORMP | Sell | ORAMED PHARMACEUTICALS INC | $3,043,000 | +2.9% | 850,000 | -37.3% | 2.74% | +7.1% |
| CRTX | New | QUINCE THERAPEUTICS INC | $2,124,818 | – | 1,411,839 | +100.0% | 1.91% | – |
| PASG | Buy | PASSAGE BIO INC | $1,937,917 | +499.6% | 2,058,767 | +510.1% | 1.74% | +524.7% |
| FBRX | FORTE BIOSCIENCES INC | $1,804,478 | +3.0% | 1,735,075 | 0.0% | 1.62% | +7.1% | |
| Sell | ENLIVEN THERAPEUTICS INC | $1,515,075 | -67.4% | 74,232 | -65.0% | 1.36% | -66.1% | |
| ABIO | ARCA BIOPHARMA INC | $1,435,068 | +2.0% | 706,930 | 0.0% | 1.29% | +6.2% | |
| TLYS | Sell | TILLYS INCcl a | $1,335,531 | -85.0% | 190,518 | -83.5% | 1.20% | -84.4% |
| LISATA THERAPEUTICS INC | $902,204 | +14.0% | 243,839 | 0.0% | 0.81% | +18.7% | ||
| VRCA | VERRICA PHARMACEUTICALS INC | $865,500 | -11.2% | 150,000 | 0.0% | 0.78% | -7.6% | |
| Sell | SURROZEN INC | $802,496 | -10.8% | 1,459,084 | -2.3% | 0.72% | -7.1% | |
| MIST | Buy | MILESTONE PHARMACEUTICALS IN | $776,625 | -10.4% | 272,500 | +23.9% | 0.70% | -6.7% |
| RVP | RETRACTABLE TECHNOLOGIES INC | $768,861 | -34.3% | 668,575 | 0.0% | 0.69% | -31.6% | |
| NXTC | NEXTCURE INC | $551,637 | +21.6% | 306,465 | 0.0% | 0.50% | +26.5% | |
| GRPH | GRAPHITE BIO INC | $395,957 | +6.1% | 152,291 | 0.0% | 0.36% | +10.2% | |
| New | CALCIMEDICA INC | $356,012 | – | 88,781 | +100.0% | 0.32% | – | |
| AVRO | New | AVROBIO INC | $243,489 | – | 256,277 | +100.0% | 0.22% | – |
| New | MEI PHARMA INC | $151,116 | – | 22,966 | +100.0% | 0.14% | – | |
| New | INVIVYD INC | $141,431 | – | 134,696 | +100.0% | 0.13% | – | |
| RAIN | New | RAIN ONCOLOGY INC | $87,511 | – | 72,926 | +100.0% | 0.08% | – |
| NLTX | NEOLEUKIN THERAPEUTICS INC | $19,712 | +18.6% | 23,749 | 0.0% | 0.02% | +28.6% | |
| ACET | Exit | ADICET BIO INC | $0 | – | -30,000 | -100.0% | -0.15% | – |
| Exit | CARISMA THERAPEUTICS INC | $0 | – | -411,398 | -100.0% | -1.10% | – | |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -1,087,961 | -100.0% | -1.74% | – |
| MTCR | Exit | METACRINE INC | $0 | – | -6,167,458 | -100.0% | -3.04% | – |
| Exit | EMBARK TECHNOLOGY INC | $0 | – | -1,285,390 | -100.0% | -3.12% | – | |
| Exit | DISC MEDICINE INC | $0 | – | -208,161 | -100.0% | -3.81% | – | |
| STSA | Exit | SATSUMA PHARMACEUTICALS INC | $0 | – | -6,440,000 | -100.0% | -3.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-07-24
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR SER TR | 4 | Q3 2023 | 16.9% |
| ADVERUM BIOTECHNOLOGIES INC | 4 | Q3 2023 | 7.4% |
| ELIEM THERAPEUTICS INC | 4 | Q3 2023 | 6.4% |
| ATHIRA PHARMA INC | 4 | Q3 2023 | 4.9% |
| ASTROTECH CORP | 4 | Q3 2023 | 2.8% |
| ARCA BIOPHARMA INC | 4 | Q3 2023 | 1.9% |
| FORTE BIOSCIENCES INC | 4 | Q3 2023 | 1.6% |
| VERRICA PHARMACEUTICALS INC | 4 | Q3 2023 | 2.9% |
| PASSAGE BIO INC | 4 | Q3 2023 | 1.7% |
| RETRACTABLE TECHNOLOGIES INC | 4 | Q3 2023 | 1.0% |
View BML Capital Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-04-24 |
| 13F-HR | 2024-04-23 |
| 13F-HR/A | 2024-02-02 |
| 13F-HR | 2024-01-30 |
| 13F-HR | 2023-10-23 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-14 |
| 13F-HR | 2023-02-13 |
View BML Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.